Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial - Concepedia

Concepedia

Publication | Open Access

Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial

DOI Full Paper Access

17

Citations

27

References

2023

Year

Neal D. Shore, Mukaram Gazi, Christopher Pieczonka, Sean Heron, Rishi Modh, David Cahn, Laurence Belkoff, Aaron J. Berger, Brian C. Mazzarella, Joseph Veys,

European Urology Oncology

Abstract

One in 13 patients with prostate cancer carries an inherited variant that may be actionable for the patient's current care or prevention of future cancer, and could benefit from expanded testing criteria.

References

	Year	Citations

Page 1